Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
The Times Mirror Company; Los Angeles Times - September 13, 1994
Marlene Cimons; Times Staff Writer
The activist community continues to support a 1992 decision by the agency to license therapies based on early signs--known as "surrogate markers"--that may predict, but do not prove, future clinical benefits. Some activists, however, have become increasingly unhappy over what they view as inadequate follow-through by drug companies and the FDA.
This has led to a lack of sufficient information about clinical benefits, "forcing people with HIV infection to make treatment decisions in the dark," said the Treatment Action Group, a New York-based activist organization that has spearheaded the effort to reopen the discussion.
The FDA's antiviral drugs advisory committee sponsored a meeting to listen to opinions on the subject but is not expected to make any immediate decisions or changes in the current policy. The panel is scheduled to make its views known today.
Insisting that it still favors accelerated approval, Treatment Action Group nevertheless said that the agency "has not insisted on adequate and well-controlled confirmatory studies, and industry has not provided sufficient post-marketing information on whether accelerated-approved drugs actually work."
FDA spokesman Jim O'Hara said the agency "remains committed to accelerated approval but we've always realized that it could well be subject to mid-course correction."
Nevertheless, many speakers Monday--including some who told poignant personal stories--said they feared that the current discussion would endanger the accelerated approval policy, which they believe it is crucial to maintain.
Dr. Thomas McGee, a Los Angeles physician with an AIDS practice, complained that his patients were being "protected to death," when they were denied access to experimental therapies.
Martin Delaney, founding director of Project Inform, said he thought it "unfortunate that this meeting has linked the discussion of how to get information from clinical trials with the issue of accelerated approval.
"It would have been preferable to raise the legitimate issue of getting better data as an independent concern, rather than making it a forum for debating the merits of accelerated approval," he added. "The issues can and do stand on their own."
940913
LT940903
Copyright © 1994 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .